Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are down on Friday as the company announced initial clinical data regarding its AlloNK (AB-101) in combination with rituximab for autoimmune diseases and a $300 million private placement.